Literature DB >> 17016041

Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis.

Florian Then Bergh1, Alexander Niklas, Angelika Strauss, Nicolas von Ahsen, Dietger Niederwieser, Johannes Schwarz, Armin Wagner, Haifa K Al-Ali.   

Abstract

A woman with relapsing-remitting multiple sclerosis (MS) was treated with oral azathioprine (AZA) for 4 years and subsequently switched to interferon-beta1a. Five years later, leukopenia developed and resolved after interferon was discontinued; MS treatment was changed to copolymer-1. Recurrent pancytopenia subsequently led to diagnosis of myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 (MDS 5q-). Within several months, unusually rapid for this subtype, MDS progressed to secondary acute myeloid leukemia. While AZA is the probable cause for the chromosomal deletion and MDS, combined or sequential immunomodulatory therapies may permit clonal expansion of malignant hematopoietic progenitors. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016041     DOI: 10.1159/000094683

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

Review 1.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 2.  Azathioprine. Safety profile in multiple sclerosis patients.

Authors:  L La Mantia; N Mascoli; C Milanese
Journal:  Neurol Sci       Date:  2007-12       Impact factor: 3.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.